{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T11:34:43Z","timestamp":1778499283196,"version":"3.51.4"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11910-025-01467-x","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T07:32:31Z","timestamp":1763364751000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Nocturnal Hypokinesia and Early Morning OFF in Parkinson\u2019s Disease: State-of-the-Art and Systematic Review of Treatment Availability"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6379-4579","authenticated-orcid":false,"given":"Jirada","family":"Sringean","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell Anne Marie","family":"Carandang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliza","family":"Zhunusova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roongroj","family":"Bhidayasiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"1467_CR1","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/mds.870130606","volume":"13","author":"E Tandberg","year":"1998","unstructured":"Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with parkinson\u2019s disease. Mov Disord. 1998;13:895\u20139.","journal-title":"Mov Disord"},{"key":"1467_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1468-1331.2007.01998.x","volume":"15","author":"B Porter","year":"2008","unstructured":"Porter B, Macfarlane R, Walker R. The frequency and nature of sleep disorders in a community-based population of patients with parkinson\u2019s disease. Eur J Neurol. 2008;15:50\u20134.","journal-title":"Eur J Neurol"},{"key":"1467_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1471-2377-12-71","volume":"12","author":"E Svensson","year":"2012","unstructured":"Svensson E, Beiske AG, Loge JH, Beiske KK, Sivertsen B. Sleep problems in parkinson\u2019s disease: a community-based study in Norway. BMC Neurol. 2012;12:71.","journal-title":"BMC Neurol"},{"issue":"Suppl 1","key":"1467_CR4","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1007\/s00702-014-1199-x","volume":"121","author":"R Bhidayasiri","year":"2014","unstructured":"Bhidayasiri R, Mekawichai P, Jitkritsadakul O, Panyakaew P, Kaewwilai L, Boonrod N, et al. Nocturnal journey of body and Mind in parkinson\u2019s disease: the manifestations, risk factors and their relationship to daytime symptoms. Evidence from the NIGHT-PD study. J Neural Transm (Vienna). 2014;121(Suppl 1):S59\u201368.","journal-title":"J Neural Transm (Vienna)"},{"key":"1467_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/00002826-198812000-00004","volume":"11","author":"AJ Lees","year":"1988","unstructured":"Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of parkinson\u2019s disease. Clin Neuropharmacol. 1988;11:512\u20139.","journal-title":"Clin Neuropharmacol"},{"key":"1467_CR6","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.sleep.2013.03.010","volume":"14","author":"M Louter","year":"2013","unstructured":"Louter M, van Sloun RJ, Pevernagie DA, Arends JB, Cluitmans PJ, Bloem BR, et al. Subjectively impaired bed mobility in Parkinson disease affects sleep efficiency. Sleep Med. 2013;14:668\u201374.","journal-title":"Sleep Med"},{"key":"1467_CR7","doi-asserted-by":"publisher","first-page":"681773","DOI":"10.3389\/fnagi.2021.681773","volume":"13","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zhang ZE, Shi D, Zhao Y, Huang L, Zhao Y, et al. Nocturnal sleep problems mediate the impact on quality of life of early morning off in parkinson\u2019s disease. Front Aging Neurosci. 2021;13:681773.","journal-title":"Front Aging Neurosci"},{"key":"1467_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.parkreldis.2022.04.007","volume":"98","author":"F Dijkstra","year":"2022","unstructured":"Dijkstra F, de Volder I, Viaene M, Cras P, Crosiers D. Impaired bed mobility in prediagnostic and de Novo parkinson\u2019s disease. Parkinsonism Relat Disord. 2022;98:47\u201352.","journal-title":"Parkinsonism Relat Disord"},{"key":"1467_CR9","doi-asserted-by":"publisher","first-page":"108493","DOI":"10.1016\/j.clineuro.2024.108493","volume":"245","author":"H Kataoka","year":"2024","unstructured":"Kataoka H, Sugie K. Early-morning OFF in parkinson\u2019s disease: A systematic literature review and current therapeutics. Clin Neurol Neurosurg. 2024;245:108493.","journal-title":"Clin Neurol Neurosurg"},{"key":"1467_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.parkreldis.2015.11.003","volume":"23","author":"J Sringean","year":"2016","unstructured":"Sringean J, Taechalertpaisarn P, Thanawattano C, Bhidayasiri R. How well do parkinson\u2019s disease patients turn in bed? Quantitative analysis of nocturnal hypokinesia using multisite wearable inertial sensors. Parkinsonism Relat Disord. 2016;23:10\u20136.","journal-title":"Parkinsonism Relat Disord"},{"key":"1467_CR11","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s10072-017-2967-9","volume":"38","author":"T Gazibara","year":"2017","unstructured":"Gazibara T, Kisic-Tepavcevic D, Svetel M, Tomic A, Stankovic I, Kostic V, et al. Dynamics of change in self-reported disability among persons with parkinson\u2019s disease after 2 years of follow-up. Neurol Sci. 2017;38:1415\u201321.","journal-title":"Neurol Sci"},{"key":"1467_CR12","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/JNN.0000000000000544","volume":"52","author":"JY Shin","year":"2020","unstructured":"Shin JY, Habermann B. Key activities of caregivers for individuals with Parkinson disease: A secondary analysis. J Neurosci Nurs. 2020;52:284\u20138.","journal-title":"J Neurosci Nurs"},{"issue":"Suppl 1","key":"1467_CR13","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1007\/s00702-014-1200-8","volume":"121","author":"P Viwattanakulvanid","year":"2014","unstructured":"Viwattanakulvanid P, Kaewwilai L, Jitkritsadakul O, Brenden NR, Setthawatcharawanich S, Boonrod N, et al. The impact of the nocturnal disabilities of parkinson\u2019s disease on caregivers\u2019 burden: implications for interventions. J Neural Transm (Vienna). 2014;121(Suppl 1):S15\u201324.","journal-title":"J Neural Transm (Vienna)"},{"key":"1467_CR14","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1111\/j.1532-5415.2012.03966.x","volume":"60","author":"M Louter","year":"2012","unstructured":"Louter M, Munneke M, Bloem BR, Overeem S. Nocturnal hypokinesia and sleep quality in parkinson\u2019s disease. J Am Geriatr Soc. 2012;60:1104\u20138.","journal-title":"J Am Geriatr Soc"},{"key":"1467_CR15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jocn.2018.06.016","volume":"54","author":"F Xue","year":"2018","unstructured":"Xue F, Wang FY, Mao CJ, Guo SP, Chen J, Li J, et al. Analysis of nocturnal hypokinesia and sleep quality in parkinson\u2019s disease. J Clin Neurosci. 2018;54:96\u2013101.","journal-title":"J Clin Neurosci"},{"key":"1467_CR16","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.5665\/sleep.4994","volume":"38","author":"A Stefani","year":"2015","unstructured":"Stefani A, Gabelia D, Mitterling T, Poewe W, H\u00f6gl B, Frauscher B. A prospective Video-Polysomnographic analysis of movements during physiological sleep in 100 healthy sleepers. Sleep. 2015;38:1479\u201387.","journal-title":"Sleep"},{"key":"1467_CR17","first-page":"100258","volume":"10","author":"J Sringean","year":"2024","unstructured":"Sringean J, Udomsirithamrong O, Bhidayasiri R. Too little or too much nocturnal movements in parkinson\u2019s disease: A practical guide to managing the unseen. Clin Park Relat Disord. 2024;10:100258.","journal-title":"Clin Park Relat Disord"},{"key":"1467_CR18","doi-asserted-by":"publisher","first-page":"922218","DOI":"10.3389\/fmedt.2022.922218","volume":"4","author":"J Sringean","year":"2022","unstructured":"Sringean J, Thanawattano C, Bhidayasiri R. Technological evaluation of strategies to get out of bed by people with parkinson\u2019s disease: insights from multisite wearable sensors. Front Med Technol. 2022;4:922218.","journal-title":"Front Med Technol"},{"key":"1467_CR19","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/02703180802560934","volume":"27","author":"J Mount","year":"2009","unstructured":"Mount J, Cianci H, Weiman R, Costa J, Tabibian H, Prochaska J. How people with parkinson\u2019s disease get out of bed. Phys Occup Therapy Geriatr. 2009;27:333\u201359.","journal-title":"Phys Occup Therapy Geriatr"},{"key":"1467_CR20","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1136\/jnnp.61.6.645","volume":"61","author":"MJ Steiger","year":"1996","unstructured":"Steiger MJ, Thompson PD, Marsden CD. Disordered axial movement in parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1996;61:645\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1467_CR21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Tredici KD, R\u00fcb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic parkinson\u2019s disease. Neurobiol Aging. 2003;24:197\u2013211.","journal-title":"Neurobiol Aging"},{"key":"1467_CR22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2217\/nmt-2017-0016","volume":"7","author":"R Bhidayasiri","year":"2017","unstructured":"Bhidayasiri R, Sringean J, Thanawattano C. Impaired bed mobility: quantitative torque analysis with axial inertial sensors. Neurodegener Dis Manag. 2017;7:235\u201343.","journal-title":"Neurodegener Dis Manag"},{"key":"1467_CR23","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/mds.28006","volume":"35","author":"A Mirelman","year":"2020","unstructured":"Mirelman A, Hillel I, Rochester L, Del Din S, Bloem BR, Avanzino L, et al. Tossing and turning in bed: nocturnal movements in parkinson\u2019s disease. Mov Disord. 2020;35:959\u201368.","journal-title":"Mov Disord"},{"key":"1467_CR24","doi-asserted-by":"publisher","first-page":"450","DOI":"10.14348\/molcells.2017.0065","volume":"40","author":"J Kim","year":"2017","unstructured":"Kim J, Jang S, Choe HK, Chung S, Son GH, Kim K. Implications of circadian rhythm in dopamine and mood regulation. Mol Cells. 2017;40:450\u20136.","journal-title":"Mol Cells"},{"key":"1467_CR25","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1001\/archneur.62.3.467","volume":"62","author":"G Levy","year":"2005","unstructured":"Levy G, Louis ED, Cote L, Perez M, Mejia-Santana H, Andrews H, et al. Contribution of aging to the severity of different motor signs in Parkinson disease. Arch Neurol. 2005;62:467\u201372.","journal-title":"Arch Neurol"},{"key":"1467_CR26","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/S1474-4422(11)70067-9","volume":"10","author":"KM Doherty","year":"2011","unstructured":"Doherty KM, van de Warrenburg BP, Peralta MC, Silveira-Moriyama L, Azulay J-P, Gershanik OS, et al. Postural deformities in parkinson\u2019s disease. Lancet Neurol. 2011;10:538\u201349.","journal-title":"Lancet Neurol"},{"key":"1467_CR27","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1007\/s10072-022-06030-x","volume":"43","author":"L Gao","year":"2022","unstructured":"Gao L, Huang W, Cai L, Li H. Association between sleep disturbances and pain subtypes in parkinson\u2019s disease. Neurol Sci. 2022;43:4785\u201390.","journal-title":"Neurol Sci"},{"key":"1467_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/mds.25708","volume":"29","author":"S Marrinan","year":"2014","unstructured":"Marrinan S, Emmanuel AV, Burn DJ. Delayed gastric emptying in parkinson\u2019s disease. Mov Disord. 2014;29:23\u201332.","journal-title":"Mov Disord"},{"key":"1467_CR29","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.parkreldis.2011.12.004","volume":"18","author":"ZS Heetun","year":"2012","unstructured":"Heetun ZS, Quigley EM. Gastroparesis and parkinson\u2019s disease: a systematic review. Parkinsonism Relat Disord. 2012;18:433\u201340.","journal-title":"Parkinsonism Relat Disord"},{"key":"1467_CR30","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1517\/14656566.7.10.1399","volume":"7","author":"F Stocchi","year":"2006","unstructured":"Stocchi F. The Levodopa wearing-off phenomenon in parkinson\u2019s disease: Pharmacokinetic considerations. Expert Opin Pharmacother. 2006;7:1399\u2013407.","journal-title":"Expert Opin Pharmacother"},{"key":"1467_CR31","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jns.2016.12.045","volume":"373","author":"J Sringean","year":"2017","unstructured":"Sringean J, Anan C, Thanawattano C, Bhidayasiri R. Time for a strategy in night-time dopaminergic therapy? An objective sensor-based analysis of nocturnal hypokinesia and sleeping positions in parkinson\u2019s disease. J Neurol Sci. 2017;373:244\u20138.","journal-title":"J Neurol Sci"},{"key":"1467_CR32","doi-asserted-by":"publisher","first-page":"105713","DOI":"10.1016\/j.clineuro.2020.105713","volume":"192","author":"J Sringean","year":"2020","unstructured":"Sringean J, Anan C, Bhidayasiri R. Impaired ability to turn in bed in parkinson\u2019s disease as a potential rare cause of positional asphyxia: a sensor-based analysis. Clin Neurol Neurosurg. 2020;192:105713.","journal-title":"Clin Neurol Neurosurg"},{"key":"1467_CR33","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3233\/NRE-210301","volume":"50","author":"S Taniguchi","year":"2022","unstructured":"Taniguchi S, D\u2019Cruz N, Nakagoshi M, Osaki T, Nieuwboer A. Determinants of impaired bed mobility in parkinson\u2019s disease: impact of hip muscle strength and motor symptoms. NeuroRehabilitation. 2022;50:445\u201352.","journal-title":"NeuroRehabilitation"},{"key":"1467_CR34","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.parkreldis.2015.08.010","volume":"21","author":"M Sommerauer","year":"2015","unstructured":"Sommerauer M, Werth E, Poryazova R, Gavrilov YV, Hauser S, Valko PO. Bound to supine sleep: parkinson\u2019s disease and the impact of nocturnal immobility. Parkinsonism Relat Disord. 2015;21:1269\u201372.","journal-title":"Parkinsonism Relat Disord"},{"key":"1467_CR35","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1093\/brain\/awz111","volume":"142","author":"SM Fereshtehnejad","year":"2019","unstructured":"Fereshtehnejad SM, Yao C, Pelletier A, Montplaisir JY, Gagnon JF, Postuma RB. Evolution of prodromal parkinson\u2019s disease and dementia with lewy bodies: a prospective study. Brain. 2019;142:2051\u201367.","journal-title":"Brain"},{"key":"1467_CR36","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.cmpb.2018.04.029","volume":"162","author":"SL Chiang","year":"2018","unstructured":"Chiang SL, Lin CH, Hsu YD, Wei SH, Sung WH, Lu LH, et al. Analysis of trunk rolling in parkinson\u2019s disease patients using a mattress mobility detection system. Comput Methods Programs Biomed. 2018;162:157\u201363.","journal-title":"Comput Methods Programs Biomed"},{"key":"1467_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2016.02.066","volume":"364","author":"R Onozawa","year":"2016","unstructured":"Onozawa R, Tsugawa J, Tsuboi Y, Fukae J, Mishima T, Fujioka S. The impact of early morning off in parkinson\u2019s disease on patient quality of life and caregiver burden. J Neurol Sci. 2016;364:1\u20135.","journal-title":"J Neurol Sci"},{"key":"1467_CR38","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/ene.13895","volume":"26","author":"F Stocchi","year":"2019","unstructured":"Stocchi F, Coletti C, Bonassi S, Radicati FG, Vacca L. Early-morning OFF and Levodopa dose failures in patients with parkinson\u2019s disease attending a routine clinical appointment using Time-to-ON questionnaire. Eur J Neurol. 2019;26:821\u20136.","journal-title":"Eur J Neurol"},{"key":"1467_CR39","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.parkreldis.2014.09.013","volume":"20","author":"A Rizos","year":"2014","unstructured":"Rizos A, Martinez-Martin P, Odin P, Antonini A, Kessel B, Kozul TK, et al. Characterizing motor and non-motor aspects of early-morning off periods in parkinson\u2019s disease: an international multicenter study. Parkinsonism Relat Disord. 2014;20:1231\u20135.","journal-title":"Parkinsonism Relat Disord"},{"issue":"Suppl 1","key":"1467_CR40","doi-asserted-by":"publisher","first-page":"S127","DOI":"10.1016\/j.parkreldis.2015.09.049","volume":"22","author":"R Bhidayasiri","year":"2016","unstructured":"Bhidayasiri R, Sringean J, Thanawattano C. Sensor-based evaluation and treatment of nocturnal hypokinesia in parkinson\u2019s disease: an evidence-based review. Parkinsonism Relat Disord. 2016;22(Suppl 1):S127\u201333.","journal-title":"Parkinsonism Relat Disord"},{"key":"1467_CR41","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement disorder Society-sponsored revision of the unified parkinson\u2019s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23:2129\u201370.","journal-title":"Mov Disord"},{"key":"1467_CR42","doi-asserted-by":"crossref","unstructured":"Zampogna A, Manoni A, Asci F, Liguori C, Irrera F, Suppa A. Shedding light on nocturnal movements in Parkinson\u2019s Disease: evidence from Wearable Technologies. Sens (Basel) 2020;20.","DOI":"10.3390\/s20185171"},{"key":"1467_CR43","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/mds.23476","volume":"26","author":"C Trenkwalder","year":"2011","unstructured":"Trenkwalder C, Kohnen R, Hogl B, Metta V, Sixel-Doring F, Frauscher B, et al. Parkinson\u2019s disease sleep scale\u2013validation of the revised version PDSS-2. Mov Disord. 2011;26:644\u201352.","journal-title":"Mov Disord"},{"key":"1467_CR44","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.parkreldis.2018.09.023","volume":"61","author":"R Bhidayasiri","year":"2019","unstructured":"Bhidayasiri R, Phokaewvarangkul O, Sringean J, Martinez-Martin P, Anan C, Kantachadvanich N, et al. Evaluation of nocturnal hypokinesia in parkinson\u2019s disease using a novel patient\/proxy questionnaire and correlations with objective monitoring. Parkinsonism Relat Disord. 2019;61:219\u201323.","journal-title":"Parkinsonism Relat Disord"},{"key":"1467_CR45","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1002\/mds.21596","volume":"22","author":"KR Chaudhuri","year":"2007","unstructured":"Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, et al. The metric properties of a novel non-motor symptoms scale for parkinson\u2019s disease: results from an international pilot study. Mov Disord. 2007;22:1901\u201311.","journal-title":"Mov Disord"},{"key":"1467_CR46","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.parkreldis.2018.01.008","volume":"50","author":"R Bhidayasiri","year":"2018","unstructured":"Bhidayasiri R, Trenkwalder C. Getting a good night sleep? The importance of recognizing and treating nocturnal hypokinesia in parkinson\u2019s disease. Parkinsonism Relat Disord. 2018;50:10\u20138.","journal-title":"Parkinsonism Relat Disord"},{"key":"1467_CR47","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/jnnp.73.6.629","volume":"73","author":"KR Chaudhuri","year":"2002","unstructured":"Chaudhuri KR, Pal S, DiMarco A, Whately-Smith C, Bridgman K, Mathew R, Pezzela FR, Forbes A, H\u00f6gl B, Trenkwalder C. The parkinson\u2019s disease sleep scale: A new instrument for assessing sleep and nocturnal disability in parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2002;73:629\u201335.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1467_CR48","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1136\/jnnp.61.1.70","volume":"61","author":"AGWW de Boer","year":"1996","unstructured":"de Boer AGWW, Speelman JD, de Haes JC. Quality of life in patients with parkinson\u2019s disease: development of a questionnaire. J Neurol Neurosurg Psychiatry. 1996;61:70\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1467_CR49","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1474-4422(16)00057-0","volume":"15","author":"A Iranzo","year":"2016","unstructured":"Iranzo A, Santamaria J, Tolosa E. Idiopathic rapid eye movement sleep behaviour disorder: diagnosis, management, and the need for neuroprotective interventions. Lancet Neurol. 2016;15:405\u201319.","journal-title":"Lancet Neurol"},{"key":"1467_CR50","doi-asserted-by":"crossref","unstructured":"Bougea A. Application of wearable sensors in parkinson\u2019s disease: state of the Art. J Sens Actuator Networks 2025;14.","DOI":"10.3390\/jsan14020023"},{"issue":"Suppl 1","key":"1467_CR51","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1016\/j.parkreldis.2016.11.016","volume":"33","author":"R Bhidayasiri","year":"2016","unstructured":"Bhidayasiri R, Sringean J, Anan C, Boonpang K, Thanawattano C, Ray Chaudhuri K. Quantitative demonstration of the efficacy of night-time apomorphine infusion to treat nocturnal hypokinesia in parkinson\u2019s disease using wearable sensors. Parkinsonism Relat Disord. 2016;33(Suppl 1):S36\u201341.","journal-title":"Parkinsonism Relat Disord"},{"issue":"Suppl 1","key":"1467_CR52","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000058048","volume":"46","author":"S Katayama","year":"2001","unstructured":"Katayama S. Actigraph analysis of diurnal motor fluctuations during dopamine agonist therapy. Eur Neurol. 2001;46(Suppl 1):11\u20137.","journal-title":"Eur Neurol"},{"key":"1467_CR53","doi-asserted-by":"crossref","unstructured":"Poplawska-Domaszewicz K, Limbachiya N, Lau YH, Chaudhuri KR. Parkinson\u2019s Kinetigraph for wearable sensor detection of clinically unrecognized early-morning Akinesia in Parkinson\u2019s Disease: a case report-based observation. Sens (Basel) 2024;24.","DOI":"10.3390\/s24103045"},{"key":"1467_CR54","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1109\/JBHI.2018.2825020","volume":"23","author":"M Takano","year":"2019","unstructured":"Takano M, Ueno A. Noncontact In-Bed measurements of physiological and behavioral signals using an integrated Fabric-Sheet sensing scheme. IEEE J Biomedical Health Inf. 2019;23:618\u201330.","journal-title":"IEEE J Biomedical Health Inf"},{"key":"1467_CR55","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1212\/WNL.43.4.677","volume":"43","author":"R Pahwa","year":"1993","unstructured":"Pahwa R, Busenbark K, Huber SJ, Michalek D, Hubble JP, Koller WC. Clinical experience with controlled-release carbidopa\/levodopa in parkinson\u2019s disease. Neurology. 1993;43:677\u201381.","journal-title":"Neurology"},{"issue":"Suppl 1","key":"1467_CR56","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1007\/PL00007731","volume":"245","author":"F Stocchi","year":"1998","unstructured":"Stocchi F, Barbato L, Nordera G, Berardelli A, Ruggieri S. Sleep disorders in parkinson\u2019s disease. J Neurol. 1998;245(Suppl 1):S15\u20138.","journal-title":"J Neurol"},{"key":"1467_CR57","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1212\/WNL.46.4.1059","volume":"46","author":"R Pahwa","year":"1996","unstructured":"Pahwa R, Lyons K, McGuire D, Dubinsky R, Hubble JP, Koller WC. Early morning akinesia in parkinson\u2019s disease: effect of standard carbidopa\/levodopa and sustained-release carbidopa\/levodopa. Neurology. 1996;46:1059\u201362.","journal-title":"Neurology"},{"key":"1467_CR58","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/j.1365-2125.1987.tb03223.x","volume":"24","author":"AL Leeman","year":"1987","unstructured":"Leeman AL, O\u2019Neill CJ, Nicholson PW, Deshmukh AA, Denham MJ, Royston JP, et al. Parkinson\u2019s disease in the elderly: response to and optimal spacing of night time dosing with Levodopa. Br J Clin Pharmacol. 1987;24:637\u201343.","journal-title":"Br J Clin Pharmacol"},{"key":"1467_CR59","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1159\/000117364","volume":"30","author":"C Pacchetti","year":"1990","unstructured":"Pacchetti C, Martignoni E, Sibilla L, Bruggi P, Turla M, Nappi G. Effectiveness of Madopar HBS plus Madopar standard in patients with fluctuating parkinson\u2019s disease: two years of follow-up. Eur Neurol. 1990;30:319\u201323.","journal-title":"Eur Neurol"},{"key":"1467_CR60","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000116207","volume":"27","author":"AJ Lees","year":"1987","unstructured":"Lees AJ. A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in parkinson\u2019s disease. Eur Neurol. 1987;27:126\u201334.","journal-title":"Eur Neurol"},{"key":"1467_CR61","first-page":"32","volume":"93","author":"M Van den Kerchove","year":"1993","unstructured":"Van den Kerchove M, Jacquy J, Gonce M, De Deyn PP. Sustained-release Levodopa in parkinsonian patients with nocturnal disabilities. Acta Neurol Belg. 1993;93:32\u20139.","journal-title":"Acta Neurol Belg"},{"key":"1467_CR62","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0303-8467(88)80007-6","volume":"90","author":"ENH Jansen","year":"1988","unstructured":"Jansen ENH, Meerwaldt JD. Madopar HBS in Parkinson patients with nocturnal akinesia. Clin Neurol Neurosurg. 1988;90:35\u20139.","journal-title":"Clin Neurol Neurosurg"},{"key":"1467_CR63","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.3233\/JPD-223295","volume":"12","author":"KR Chaudhuri","year":"2022","unstructured":"Chaudhuri KR, Antonini A, Pahwa R, Odin P, Titova N, Thakkar S, et al. Effects of Levodopa-Carbidopa intestinal gel on dyskinesia and Non-Motor symptoms including sleep: results from a Meta-Analysis with 24-Month Follow-Up. J Parkinson\u2019s Disease. 2022;12:2071\u201383.","journal-title":"J Parkinson\u2019s Disease"},{"key":"1467_CR64","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1007\/s10072-016-2664-0","volume":"37","author":"L Lopiano","year":"2016","unstructured":"Lopiano L, Modugno N, Marano P, Sensi M, Meco G, Cannas A, et al. Motor outcomes in patients with advanced parkinson\u2019s disease treated with levodopa\/carbidopa intestinal gel in italy: an interim analysis from the GREENFIELD observational study. Neurol Sci. 2016;37:1785\u201392.","journal-title":"Neurol Sci"},{"key":"1467_CR65","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1212\/WNL.62.6_suppl_4.S27","volume":"62","author":"DM Swope","year":"2004","unstructured":"Swope DM. Rapid treatment of wearing off in parkinson\u2019s disease. Neurology. 2004;62:S27\u201331.","journal-title":"Neurology"},{"key":"1467_CR66","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2165\/00002512-199710050-00002","volume":"10","author":"MC Kurth","year":"1997","unstructured":"Kurth MC. Using liquid Levodopa in the treatment of parkinson\u2019s disease. A practical guide. Drugs Aging. 1997;10:332\u201340.","journal-title":"Drugs Aging"},{"key":"1467_CR67","doi-asserted-by":"crossref","unstructured":"Fornadi F, Milani F, Werner M, editors. Madopar dispersible in the treatment of advanced Parkinson\u2019s disease. Clinical Neuropharmacology; 1995.","DOI":"10.1097\/00002826-199417003-00003"},{"key":"1467_CR68","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/WNF.0000000000000540","volume":"46","author":"RA Hauser","year":"2023","unstructured":"Hauser RA, LeWitt PA, Waters CH, Grosset DG, Blank B. The clinical development of Levodopa inhalation powder. Clin Neuropharmacol. 2023;46:66\u201378.","journal-title":"Clin Neuropharmacol"},{"key":"1467_CR69","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.parkreldis.2019.03.026","volume":"64","author":"RA Hauser","year":"2019","unstructured":"Hauser RA, Isaacson SH, Ellenbogen A, Safirstein BE, Truong DD, Komjathy SF, et al. Orally inhaled Levodopa (CVT-301) for early morning OFF periods in parkinson\u2019s disease. Parkinsonism Relat Disord. 2019;64:175\u201380.","journal-title":"Parkinsonism Relat Disord"},{"key":"1467_CR70","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s40120-023-00533-1","volume":"12","author":"J Aldred","year":"2023","unstructured":"Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F, et al. Continuous subcutaneous Foslevodopa\/Foscarbidopa in parkinson\u2019s disease: safety and efficacy results from a 12-Month, Single-Arm, Open-Label, phase 3 study. Neurol Ther. 2023;12:1937\u201358.","journal-title":"Neurol Ther"},{"key":"1467_CR71","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.parkreldis.2017.08.010","volume":"44","author":"R Bhidayasiri","year":"2017","unstructured":"Bhidayasiri R, Sringean J, Chaiwong S, Anan C, Penkeaw N, Leaknok A, et al. Rotigotine for nocturnal hypokinesia in parkinson\u2019s disease: quantitative analysis of efficacy from a randomized, placebo-controlled trial using an axial inertial sensor. Parkinsonism Relat Disord. 2017;44:124\u20138.","journal-title":"Parkinsonism Relat Disord"},{"key":"1467_CR72","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/WNF.0000000000000501","volume":"45","author":"K Suzuki","year":"2022","unstructured":"Suzuki K, Funakoshi K, Fujita H, Hirata K. The effect of rotigotine on cognitive Function, daytime sleepiness, and sleep problems in Parkinson disease: an Open-Label pilot study. Clin Neuropharmacol. 2022;45:61\u20134.","journal-title":"Clin Neuropharmacol"},{"key":"1467_CR73","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1517\/14656566.2011.604031","volume":"12","author":"L Ghys","year":"2011","unstructured":"Ghys L, Erwin S, John W, Boroojerdi B. Effect of rotigotine on sleep and quality of life in parkinson\u2019s disease patients: post hoc analysis of RECOVER patients who were symptomatic at baseline. Expert Opin Pharmacother. 2011;12:1985\u201398.","journal-title":"Expert Opin Pharmacother"},{"key":"1467_CR74","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/mds.23441","volume":"26","author":"C Trenkwalder","year":"2011","unstructured":"Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, et al. Rotigotine effects on early morning motor function and sleep in parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26:90\u20139.","journal-title":"Mov Disord"},{"key":"1467_CR75","first-page":"475630","volume":"2015","author":"F Vallderiola","year":"2015","unstructured":"Vallderiola F, Compta Y, Aparicio J, Tarradellas J, Salazar G, Oliver JM, et al. Effects of Night-Time use of rotigotine on nocturnal symptoms in parkinson\u2019s disease. Parkinsons Dis. 2015;2015:475630.","journal-title":"Parkinsons Dis"},{"key":"1467_CR76","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s00702-010-0506-4","volume":"117","author":"N Giladi","year":"2010","unstructured":"Giladi N, Fichtner A, Poewe W, Boroojerdi B. Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with parkinson\u2019s disease. J Neural Transm (Vienna). 2010;117:1395\u20139.","journal-title":"J Neural Transm (Vienna)"},{"key":"1467_CR77","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/WNF.0b013e3181e71166","volume":"33","author":"P Dusek","year":"2010","unstructured":"Dusek P, Buskov\u00e1 J, R\u016fzicka E, Majerov\u00e1 V, Srp A, Jech R, et al. Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease. Clin Neuropharmacol. 2010;33:186\u201390.","journal-title":"Clin Neuropharmacol"},{"key":"1467_CR78","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1468-1331.2011.03442.x","volume":"19","author":"K Ray Chaudhuri","year":"2012","unstructured":"Ray Chaudhuri K, Martinez-Martin P, Rolfe KA, Cooper J, Rockett CB, Giorgi L, et al. Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced parkinson\u2019s disease. Eur J Neurol. 2012;19:105\u201313.","journal-title":"Eur J Neurol"},{"key":"1467_CR79","first-page":"354760","volume":"2011","author":"H Reichmann","year":"2011","unstructured":"Reichmann H, Cooper J, Rolfe K, Martinez-Martin P. Sleep duration and on time during different periods of the day and night in patients with advanced parkinson\u2019s disease receiving adjunctive ropinirole prolonged release. Parkinsons Dis. 2011;2011:354760.","journal-title":"Parkinsons Dis"},{"key":"1467_CR80","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1212\/WNL.0b013e31822affdb","volume":"77","author":"AH Schapira","year":"2011","unstructured":"Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, et al. Extended-release Pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology. 2011;77:767\u201374.","journal-title":"Neurology"},{"key":"1467_CR81","first-page":"8834950","volume":"2021","author":"H Zhou","year":"2021","unstructured":"Zhou H, Li S, Yu H, Sun S, Wan X, Zhu X, et al. Efficacy and safety of Pramipexole sustained release versus immediate release formulation for nocturnal symptoms in Chinese patients with advanced parkinson\u2019s disease: A pilot study. Parkinsons Dis. 2021;2021:8834950.","journal-title":"Parkinsons Dis"},{"key":"1467_CR82","first-page":"227","volume":"34","author":"I Nakanishi","year":"2013","unstructured":"Nakanishi I, Ito H, Kondo T. Efficacy of extended-release Pramipexole on severe motor complications in advanced parkinson\u2019s disease. Therapeutic Res. 2013;34:227\u201333.","journal-title":"Therapeutic Res"},{"key":"1467_CR83","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1600-0404.1999.tb00732.x","volume":"100","author":"I Reuter","year":"1999","unstructured":"Reuter I, Ellis CM, Ray Chaudhuri K. Nocturnal subcutaneous apomorphine infusion in parkinson\u2019s disease and restless legs syndrome. Acta Neurol Scand. 1999;100:163\u20137.","journal-title":"Acta Neurol Scand"},{"key":"1467_CR84","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/mdc3.12350","volume":"4","author":"S Isaacson","year":"2017","unstructured":"Isaacson S, Lew M, Ondo W, Hubble J, Clinch T, Pagan F. Apomorphine subcutaneous injection for the management of morning akinesia in parkinson\u2019s disease. Mov Disorders Clin Pract. 2017;4:78\u201383.","journal-title":"Mov Disorders Clin Pract"},{"key":"1467_CR85","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40263-020-00782-w","volume":"35","author":"S Thakkar","year":"2021","unstructured":"Thakkar S, Fung VSC, Merola A, Rollins M, Soileau MJ, Kov\u00e1cs N. 24-Hour Levodopa-Carbidopa intestinal gel: clinical experience and practical recommendations. CNS Drugs. 2021;35:137\u201349.","journal-title":"CNS Drugs"},{"key":"1467_CR86","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/mds.28926","volume":"37","author":"E Thijssen","year":"2022","unstructured":"Thijssen E, den Heijer J, Puibert D, Moss L, Lei M, Hasegawa D, et al. A randomized trial assessing the Safety, Pharmacokinetics, and efficacy during morning off of AZ-009. Mov Disord. 2022;37:790\u20138.","journal-title":"Mov Disord"},{"key":"1467_CR87","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/mdc3.13690","volume":"10","author":"SH Isaacson","year":"2023","unstructured":"Isaacson SH, Achari M, Bhidayasiri R, Comella C, Farmer JG, Gupta F, et al. Expert consensus on the use of On-Demand treatments for OFF episodes in parkinson\u2019s disease: A modified Delphi panel. Mov Disord Clin Pract. 2023;10:652\u20137.","journal-title":"Mov Disord Clin Pract"},{"key":"1467_CR88","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/j.1468-1331.2011.03512.x","volume":"18","author":"F Stocchi","year":"2011","unstructured":"Stocchi F, Rabey JM. Effect of Rasagiline as adjunct therapy to Levodopa on severity of OFF in parkinson\u2019s disease. Eur J Neurol. 2011;18:1373\u20138.","journal-title":"Eur J Neurol"},{"key":"1467_CR89","doi-asserted-by":"publisher","first-page":"118070","DOI":"10.1016\/j.jns.2021.118070","volume":"429","author":"Y Tsuboi","year":"2021","unstructured":"Tsuboi Y, Koebis M, Kogo Y, Ishida T, Suzuki I, Nomoto M, et al. Effects of Safinamide adjunct therapy on pain in patients with parkinson\u2019s disease: post hoc analysis of a Japanese phase 2\/3 study. J Neurol Sci. 2021;429:118070.","journal-title":"J Neurol Sci"},{"key":"1467_CR90","first-page":"131","volume":"25","author":"W Poewe","year":"1987","unstructured":"Poewe W, Gerstenbrand F, Ransmayr G. Experience with selegiline in the treatment of parkinson\u2019s disease. J Neural Transm Suppl. 1987;25:131\u20135.","journal-title":"J Neural Transm Suppl"},{"key":"1467_CR91","first-page":"113","volume":"126","author":"EH Heinonen","year":"1989","unstructured":"Heinonen EH, Rinne UK, Tuominen J. Selegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long-term Levodopa treatment. Acta Neurol Scand Suppl. 1989;126:113\u20138.","journal-title":"Acta Neurol Scand Suppl"},{"key":"1467_CR92","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1600-0404.1989.tb01792.x","volume":"80","author":"C Chouza","year":"1989","unstructured":"Chouza C, Aljanati R, Scaramelli A, Medina OD, Caama\u00f1o JL, Buzo R, et al. Combination of selegiline and controlled release Levodopa in the treatment of fluctuations of clinical disability in parkinsonian patients. Acta Neurol Scand. 1989;80:127\u201337.","journal-title":"Acta Neurol Scand"},{"key":"1467_CR93","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1007\/s10072-023-07233-6","volume":"45","author":"M Bologna","year":"2024","unstructured":"Bologna M, Guerra A, Colella D, Birreci D, Costa D, Cannavacciuolo A, et al. Objective assessment of the effects of Opicapone in parkinson\u2019s disease through kinematic analysis. Neurol Sci. 2024;45:2035\u201346.","journal-title":"Neurol Sci"},{"key":"1467_CR94","doi-asserted-by":"publisher","first-page":"106971","DOI":"10.1016\/j.parkreldis.2024.106971","volume":"123","author":"RA Hauser","year":"2024","unstructured":"Hauser RA, Videnovic A, Soares-da-Silva P, Liang GS, Olson K, Jen E, et al. OFF-times before, during, and after nighttime sleep periods in parkinson\u2019s disease patients with motor fluctuations and the effects of opicapone: A post hoc analysis of diary data from BIPARK-1 and \u2013\u20092. Parkinsonism Relat Disord. 2024;123:106971.","journal-title":"Parkinsonism Relat Disord"},{"key":"1467_CR95","first-page":"8850","volume":"27","author":"A Antonini","year":"2023","unstructured":"Antonini A, Barone P, Calabresi P, Lopiano L, Morgante F, Pontieri FE, et al. The role of Opicapone in the management of parkinson\u2019s disease: an Italian consensus through a combined nominal group technique and Delphi approach. Eur Rev Med Pharmacol Sci. 2023;27:8850\u20139.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1467_CR96","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/ptj\/80.6.578","volume":"80","author":"ME Morris","year":"2000","unstructured":"Morris ME. Movement disorders in people with Parkinson disease: A model for physical therapy. Phys Ther. 2000;80:578\u201397.","journal-title":"Phys Ther"},{"key":"1467_CR97","doi-asserted-by":"crossref","unstructured":"Kataoka H, Saeki K, Yamagami Y, Sugie K, Obayashi K. Quantitative associations between objective sleep measures and early-morning mobility in Parkinson\u2019s disease: cross-sectional analysis of the PHASE study. Sleep 2020;43.","DOI":"10.1093\/sleep\/zsz203"},{"key":"1467_CR98","doi-asserted-by":"publisher","first-page":"e0212951","DOI":"10.1371\/journal.pone.0212951","volume":"14","author":"Z Rui","year":"2019","unstructured":"Rui Z, Qingling C, Xinyue Z, Xin Z, Weihong L. The related factors of sleep benefit in parkinson\u2019s disease: A systematic review and meta-analysis. PLoS ONE. 2019;14:e0212951.","journal-title":"PLoS ONE"},{"key":"1467_CR99","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3389\/fneur.2018.00697","volume":"9","author":"VD Sharma","year":"2018","unstructured":"Sharma VD, Sengupta S, Chitnis S, Amara AW. Deep brain stimulation and Sleep-Wake disturbances in Parkinson disease: A review. Front Neurol. 2018;9:697.","journal-title":"Front Neurol"},{"key":"1467_CR100","doi-asserted-by":"publisher","first-page":"502","DOI":"10.3171\/jns.2006.104.4.502","volume":"104","author":"KE Lyons","year":"2006","unstructured":"Lyons KE, Pahwa R. Effects of bilateral subthalamic nucleus stimulation on sleep, daytime sleepiness, and early morning dystonia in patients with Parkinson disease. J Neurosurg. 2006;104:502\u20135.","journal-title":"J Neurosurg"},{"key":"1467_CR101","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0090-3019(01)00533-X","volume":"56","author":"G Broggi","year":"2001","unstructured":"Broggi G, Franzini A, Ferroli P, Servello D, D\u2019Incerti L, Genitrini S, et al. Effect of bilateral subthalamic electrical stimulation in parkinson\u2019s disease. Surg Neurol. 2001;56:89\u201394. discussion \u2013\u20096.","journal-title":"Surg Neurol"},{"key":"1467_CR102","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.2174\/1570159X19666210215115718","volume":"19","author":"YJ Jung","year":"2021","unstructured":"Jung YJ, Kim HJ, Paek SH, Jeon B. Effects of deep brain stimulation on Sleep-Wake disturbances in patients with parkinson\u2019s disease: A narrative review. Curr Neuropharmacol. 2021;19:1716\u201327.","journal-title":"Curr Neuropharmacol"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-025-01467-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11910-025-01467-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-025-01467-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T09:02:51Z","timestamp":1763370171000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11910-025-01467-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":102,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1467"],"URL":"https:\/\/doi.org\/10.1007\/s11910-025-01467-x","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Non-finacial interests -Jirada Sringean and Roongroj Bhidayasiri hold patents for technology for monitoring during the night (NIGHT-Recorder)Finacial interests-Roongroj Bhidayasiri has received grants from the following agencies: the Thailand Science Research and Innovation (TSRI, Programme Management Unit for Competitiveness, C01F670185), the National Economic and Social Development Council of Thailand, Thailand Centre of Excellence for Life Sciences (TC (ERP) 31\/2568), the National Research Council of Thailand (N42A680591, N35E680087), and Chulalongkorn University (CE68_028_3000_004). He is also supported by the Royal Society of Thailand, has provided consultancy services, and has received honoraria and lecture fees from industries such as Britannia, Ipsen, Teva-Lundbeck, and Mitsubishi-Tanabe. Bhidayasiri holds patents for various innovations, including a laser-guided walking stick, a portable tremor device, technology for monitoring during the night, an electronic diary for Parkinson\u2019s disease symptoms, as well as the Parkinson insole and shoe, and anti-choking mugs. Furthermore, his copyrighted works comprise the application for screening Parkinson\u2019s disease (Check PD), a Parkinson\u2019s mascot, a daily activity diary for Parkinson\u2019s, creative dopamine-themed lyrics, and educational video content focusing on common nighttime and gastrointestinal symptoms associated with Parkinson\u2019s disease.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}